Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Contineum Therapeutics (CTNM) Amortization of Deferred Charges (2023)

Contineum Therapeutics has reported Amortization of Deferred Charges over the past 1 years, most recently at -$1000.0 for Q4 2023.

Quarterly results put Amortization of Deferred Charges at -$1000.0 for Q4 2023, changed N/A from a year ago — trailing twelve months through Sep 2024 was -$1000.0 (changed N/A YoY), and the annual figure for FY2023 was -$198000.0, changed.
Amortization of Deferred Charges for Q4 2023 was -$1000.0 at Contineum Therapeutics, up from -$223000.0 in the prior quarter.
Over the last five years, Amortization of Deferred Charges for CTNM hit a ceiling of $26000.0 in Q1 2023 and a floor of -$223000.0 in Q2 2023.